MarketScreener Strategies Genmab A/S Nasdaq

Stocks

Market Closed - Nasdaq Other stock markets 21:00:00 12/06/2026 BST			5-day change	1st Jan Change
25.08 ^USD	-0.63%		-0.28%	-18.57%

06-11	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
06-11	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI

	Genmab: Market mispricing creates opportunity as good Q1 reinforces investment thesis	May 09, 2026 at 01:05 pm
	Genmab: 2025 miss and cautious 2026 targets erode investor confidence	February 18, 2026 at 02:09 pm
	Genmab advances on earnings strength and pipeline while lower valuation opens upside	November 07, 2025 at 03:01 pm
	Genmab: A bold shift from defensive to aggressive	September 29, 2025 at 03:45 pm
	Genmab: From now on, courage to the most patient	April 01, 2025 at 03:57 pm